ERCC2 and gastric cardia carcinoma: Moreover, as for XPD Lys751Gln polymorphism, 4 [18], [20]–[22] out of 13 eligible studies were dealt with cardia gastric cancer and 2 [21], [25] with noncardia gastric cancer.